ORICORIC Pharmaceuticals, Inc.
$12.02-15% 1Y
$12.02
$7.4752 weeks$14.67
ORIC as reported
- Net income
- −$140M
Net income · +2.3% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$112M
Free cash flow · −7.5% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.32
EPS · −30% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$140M | +2.3% | Q2 2026 |
| EPS | −$1.32 | −30% | Q2 2026 |
| ROE | −34% | n/a | Q2 2026 |
| ROA | −32% | n/a | Q2 2026 |
| Free cash flow | −$112M | −7.5% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
ORIC Pharmaceuticals, Inc. (ORIC) · Net incomeNet incomeORIC Pharmaceuticals, Inc. (ORIC)